Johnson & Johnson (JNJ)vsVenus Concept Inc (VERO)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
VERO
Venus Concept Inc
$0.31
0.00%
HEALTHCARE · Cap: $578,190
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 168619% more annual revenue ($99.33B vs $58.88M). JNJ leads profitability with a 16.2% profit margin vs -92.8%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
VERO
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Intrinsic value data unavailable for VERO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -795.0% — below average capital efficiency
Revenue declined 8.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : VERO
The strongest argument for VERO centers on Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : VERO
The primary concerns for VERO are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 12.22 is elevated, increasing financial risk.
Key Dynamics to Monitor
JNJ profiles as a mature stock while VERO is a turnaround play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 31/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Venus Concept Inc
HEALTHCARE · MEDICAL DEVICES · USA
Venus Concept Inc., a medical technology company, develops, markets and offers minimally invasive and non-invasive medical aesthetic and hair restoration technologies globally. The company is headquartered in Toronto, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?